SHBG (Extended): When to Order This Test

What SHBG Actually Does

Sex hormone-binding globulin is a glycoprotein synthesized primarily in the liver. It circulates through the bloodstream and binds testosterone, dihydrotestosterone (DHT), and estradiol with high affinity, effectively sequestering these hormones from tissues that need them [1].

Only about 1 to 3% of total testosterone floats unbound ("free") in the blood. Another 30 to 44% binds loosely to albumin. The remainder, roughly 54 to 68%, is locked to SHBG and considered biologically unavailable [2]. This ratio matters. Two patients with identical total testosterone values can have drastically different free testosterone concentrations based entirely on their SHBG levels.

SHBG binds testosterone with roughly ten times the affinity it has for estradiol [1]. This means shifts in SHBG disproportionately affect androgen availability. A rise in SHBG from 30 to 60 nmol/L can halve the calculated free testosterone without changing total testosterone at all. The protein also carries a single steroid-binding site per dimer, so once saturated, additional hormone remains unbound. This saturation kinetics explains why SHBG is most clinically informative at the extremes: very high or very low concentrations.

The liver responds to a range of metabolic and hormonal signals when producing SHBG. Estrogen and thyroid hormone stimulate production. Insulin, androgens, and growth hormone suppress it [3]. That feedback loop means SHBG is not just a transport protein but a metabolic biomarker in its own right.

When the Endocrine Society Says to Order It

The 2018 Endocrine Society Clinical Practice Guideline for testosterone therapy in men with hypogonadism provides specific direction. The guideline states: "We recommend measuring SHBG concentration using a reliable assay when total testosterone concentration is near the lower limit of normal" [4]. That lower limit is generally accepted as 264 to 300 ng/dL, though the guideline acknowledges lab-specific variation.

Order the SHBG (extended) panel in these clinical scenarios. First, when total testosterone falls between 264 and 400 ng/dL and the patient reports fatigue, low libido, or erectile dysfunction. A borderline total testosterone could be functionally deficient if SHBG is elevated above 50 nmol/L.

Second, before initiating testosterone replacement therapy. Baseline SHBG helps predict dose response. Men with high SHBG often require higher initial doses of injectable testosterone, while men with low SHBG may achieve therapeutic free testosterone levels faster [4].

Third, in women being evaluated for polycystic ovary syndrome. The 2023 international evidence-based PCOS guideline recommends calculating free androgen index (FAI = total testosterone / SHBG x 100) as a diagnostic tool, noting that "calculated free testosterone or free androgen index are the most sensitive biochemical markers of hyperandrogenism" [5]. Low SHBG in this context amplifies androgen activity and contributes to hirsutism, acne, and anovulation.

Fourth, when monitoring women on oral estrogen therapy. Oral estrogens undergo first-pass hepatic metabolism and raise SHBG significantly, sometimes doubling or tripling pre-treatment values. Transdermal estrogen, by contrast, has a minimal effect on SHBG [6].

The "Extended" Panel Explained

A standard SHBG test returns a single value in nmol/L. The "extended" designation means the lab reports SHBG alongside total testosterone, albumin concentration, and a calculated free or bioavailable testosterone. Some panels also include estradiol and DHT.

The calculation method matters. The Vermeulen equation, validated against equilibrium dialysis in 2006, uses SHBG, total testosterone, and albumin to derive free testosterone [7]. This calculated value correlates well with the gold-standard equilibrium dialysis method (r = 0.9 in most validation studies) and outperforms direct analog free testosterone immunoassays, which the Endocrine Society guideline explicitly discourages using [4].

The extended panel gives clinicians four data points from a single blood draw: total testosterone, SHBG, albumin, and calculated free testosterone. Ordering them separately across multiple visits wastes time. The extended panel also reduces the chance of interpretive error; when a clinician sees only total testosterone without SHBG, borderline results get misclassified in both directions.

High SHBG: Causes and Clinical Meaning

SHBG above 57 nmol/L in men or above 144 nmol/L in women is considered elevated by most reference laboratories [8]. High SHBG traps more testosterone in the bound fraction, reducing the free hormone available to androgen receptors.

Common causes include aging (SHBG rises approximately 1 to 2% per year after age 40 in men), hyperthyroidism, liver disease (particularly hepatitis and cirrhosis, where damaged hepatocytes paradoxically overproduce SHBG), oral estrogen use, and anticonvulsant medications such as phenytoin and carbamazepine [3].

A 2010 study in the Journal of Clinical Endocrinology & Metabolism (N=3,219 men, ages 40 to 79) from the European Male Aging Study found that SHBG was a stronger predictor of symptomatic androgen deficiency than total testosterone alone [9]. Men with total testosterone above 300 ng/dL but SHBG above 60 nmol/L reported symptoms indistinguishable from men with frank hypogonadism (total testosterone <250 ng/dL). The free testosterone calculation resolved the discrepancy.

Practical strategies for patients with high SHBG who are symptomatic include weight-bearing exercise (which modestly reduces SHBG), optimizing thyroid function if subclinical hyperthyroidism is present, switching from oral to transdermal estrogen in women on HRT, and, when indicated, initiating or adjusting testosterone therapy to overcome the binding capacity [10].

Low SHBG: Causes and Clinical Meaning

SHBG below 10 nmol/L in men or below 18 nmol/L in women signals excess free hormone availability or, more often, underlying metabolic dysfunction. Low SHBG is strongly associated with insulin resistance, type 2 diabetes, obesity, hypothyroidism, and polycystic ovary syndrome [3].

A prospective analysis from the Massachusetts Male Aging Study (N=1,156 men followed for 8 to 10 years) found that each standard deviation decrease in SHBG was associated with an odds ratio of 1.58 (95% CI 1.14 to 2.19) for developing metabolic syndrome [11]. SHBG functioned as an independent predictor even after adjusting for BMI, insulin, and lipid levels.

In men, low SHBG can inflate total testosterone readings. A man with total testosterone of 600 ng/dL and SHBG of 12 nmol/L may have free testosterone well above the reference range, which can drive erythrocytosis, acne, or prostatic stimulation even without exogenous androgen use [4]. In women with PCOS, low SHBG amplifies androgen action; the free androgen index often exceeds 5 (normal <5 in women) when SHBG drops below 25 nmol/L [5].

Interventions to raise low SHBG target the root metabolic cause. Weight loss of 5 to 10% body weight consistently raises SHBG by 10 to 20% in obese patients [12]. Metformin has a modest SHBG-raising effect in insulin-resistant women. Correcting hypothyroidism with levothyroxine normalizes SHBG as thyroid hormone levels restore. Reducing exogenous androgen doses (in patients on TRT) can also allow SHBG to recover.

SHBG in Testosterone Replacement Therapy Monitoring

SHBG should be measured at baseline and during TRT follow-up because it changes the clinical picture in measurable ways. Exogenous testosterone, particularly injectable formulations, tends to suppress SHBG by 10 to 30% within the first 3 to 6 months of therapy [4]. This suppression means that total testosterone may appear to plateau or decrease while free testosterone continues to rise.

The Endocrine Society guideline recommends monitoring trough testosterone levels 3 to 6 months after initiating therapy, and calculating free testosterone if SHBG was abnormal at baseline [4]. Dr. Shalender Bhasin, lead author of the 2018 guideline, has stated in published commentary: "Reliance on total testosterone alone may lead to undertreatment of men with high SHBG and overtreatment of men with low SHBG" [4].

For men on injectable testosterone cypionate (100 to 200 mg weekly or biweekly), SHBG typically falls to the lower half of the reference range within 6 months. If SHBG drops below 15 nmol/L during TRT, free testosterone should be recalculated; the effective androgen exposure may be substantially higher than the total testosterone value suggests, increasing risk for polycythemia and cardiovascular events that the TRAVERSE trial (N=5,204) monitored over a median follow-up of 33 months [13].

Transdermal testosterone gels and patches suppress SHBG less than injectables because they avoid the supraphysiologic peaks that occur with intramuscular dosing [4]. Clinicians switching a patient from injections to gel should expect SHBG to rise modestly, which may temporarily lower free testosterone until the new steady state establishes.

SHBG in Women's Hormone Therapy

SHBG is equally relevant in female hormone management, though often overlooked. Oral estradiol and conjugated equine estrogens (CEE) undergo extensive first-pass hepatic metabolism, which stimulates SHBG synthesis. A randomized crossover study of 40 postmenopausal women showed that oral estradiol 2 mg/day increased SHBG by 97% from baseline, compared to just 12% with the transdermal 50 mcg/day patch [6].

The AACE 2017 guidelines for menopause management note that elevated SHBG during oral HRT can reduce bioavailable testosterone to levels associated with decreased libido and reduced bone formation, even when estradiol levels are well-controlled [14]. This is one reason transdermal estradiol has gained preference in many clinical settings: it delivers effective estrogen replacement without the SHBG surge that can suppress already-declining androgens in postmenopausal women.

For women on combined oral contraceptives, SHBG rises substantially, often to 100 to 200 nmol/L [15]. This rise suppresses free testosterone and free DHT, which is therapeutic for androgen-driven conditions like acne and hirsutism. However, some women on combined oral contraceptives report decreased libido; the mechanism is at least partially attributable to SHBG-mediated reduction in free testosterone. Switching to a progestin-only method or a hormonal IUD, which has minimal systemic SHBG effect, may help.

How to Interpret SHBG Results Step by Step

Start with the reference range from the reporting laboratory. Ranges vary by assay, but a commonly used set (based on LC-MS/MS validated methods) is 10 to 57 nmol/L for adult males and 18 to 144 nmol/L for adult females [8].

Next, look at the calculated free testosterone (or free androgen index in women). If total testosterone is normal but free testosterone is low, SHBG is the explanation. This pattern is common in older men, hyperthyroid patients, and women on oral estrogen.

If total testosterone is normal but free testosterone is high, suspect low SHBG. Screen for insulin resistance (fasting glucose, HbA1c, fasting insulin), thyroid dysfunction (TSH, free T4), and signs of metabolic syndrome. The American Diabetes Association recognizes low SHBG as a risk factor for type 2 diabetes and includes it in the constellation of findings that warrant glucose screening [16].

Repeat the test if results are unexpected. SHBG is relatively stable day to day (coefficient of variation around 8 to 12%), but acute illness, fasting states, and recent medication changes can transiently alter levels [2]. Morning fasting samples provide the most reproducible results.

Do not interpret SHBG in isolation. Its clinical value comes entirely from the context of total testosterone, albumin, estradiol, thyroid function, and the patient's metabolic profile.

Conditions That Shift SHBG Up or Down

SHBG production responds to a network of hepatic signals. The following conditions and medications have documented, reproducible effects on SHBG concentrations.

Factors that raise SHBG: aging, oral estrogen (HRT or contraceptives), hyperthyroidism, liver cirrhosis, HIV infection and its antiretroviral treatments (particularly protease inhibitors), anorexia nervosa, and anticonvulsants [3]. Pregnancy raises SHBG five to tenfold by the third trimester due to high circulating estrogen [15].

Factors that lower SHBG: obesity (BMI above 30 is associated with SHBG levels 30 to 50% lower than lean controls), type 2 diabetes, insulin resistance, hypothyroidism, nephrotic syndrome (urinary protein loss includes SHBG), exogenous androgens, glucocorticoid excess (Cushing syndrome), growth hormone excess (acromegaly), and progestins with androgenic activity such as levonorgestrel [3, 12].

A 2016 Mendelian randomization study published in PLOS Medicine (N=28,029 women) provided genetic evidence that higher SHBG is causally protective against type 2 diabetes, with each one standard deviation increase in genetically predicted SHBG associated with a 40% reduction in diabetes risk (OR 0.60 to 95% CI 0.44 to 0.82) [17]. This finding elevated SHBG from a passive carrier protein to an active participant in glucose metabolism.